In the release dated June 16, 2008, the URL at the end of the "About The
Institute for Eye Research (IER)" section should read www.ier.org.au
(sted www.ier.org).
The corrected release reads:
ADVANCED MEDICAL OPTICS ANNOUNCES PARTNERSHIP WITH INSTITUTE FOR EYE
RESEARCH TO DEVELOP CONTACT LENS DISINFECTANT AND CLEANING SOLUTIONS
Advanced Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in
ophthalmic surgical devices and eye care products, has announced a
collaboration with the Institute for Eye Research (IER) to develop
contact lens disinfectant and cleaning solutions and related products.
IER is a non-profit research organization that conducts collaborative
and contract research with and for industry in the area of vision
correction, eye care, the anterior eye, contact lenses, contact lens
care and patient management, to avoid contact lens complications. The
organization is a world leader in the in vitro and clinical evaluation
of silicone hydrogel lenses and their interaction with contact lens care
products using their proprietary modeling systems and databases.
"IER’s world-class
scientists and clinicians have had a major impact on the development of
contact lenses and lens care technologies,”
said AMO Executive Vice President, Research and Development Leonard
Borrmann. "We look forward to working closely
with the IER on the development of next-generation contact lens
solutions.” "Through our collaboration with AMO, we will
work to develop, test and deliver, through product innovation and
education, the best in contact lens care products,”
said IER CEO Brien Holden, PhD. "Our goal is
to develop new, safer, better and more convenient initiatives in the
field of contact lens cleaning and disinfection systems,
including the containers for storage, cleaning and disinfection.”
IER is headquartered in Sydney, Australia.
About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive
technologies and support to help eye care professionals deliver optimal
vision and lifestyle experiences to patients of all ages. Products in
the cataract line include monofocal intraocular lenses (IOLs),
phacoemulsification systems, viscoelastics, and related products used in
ocular surgery. AMO owns or has the rights to such product brands as
Tecnis®, Clariflex®
and Sensar® IOLs;
Sovereign®, Sovereign®
Compact and WhiteStar Signature™
phacoemulsification systems with WhiteStar®
technology; Healon®
viscoelastics and the Baerveldt® glaucoma shunt. Products in the refractive line include wavefront
diagnostic devices, femtosecond lasers and associated patient interface
devices; excimer laser vision correction systems and treatment cards,
and refractive implants. AMO brands in the refractive business include
iDesign™, iFS™,
Star S4 IR®,
WaveScan Wavefront®,
Advanced CustomVue™,
IntraLase®,
IntraLasik®
and ReZoom®, Tecnis®
Multifocal and Verisyse® IOLs.
Products in the eye care line include disinfecting solutions, enzymatic
cleaners, lens rewetting drops and artificial tears. Among the eye care
product brands the company possesses are COMPLETE®,
COMPLETE®
Blink-N-Clean®,
Consept®F, Consept®
1 Step, Oxysept® 1
Step, UltraCare®,
Ultrazyme®, Total
Care™ and blink™ branded products. AMO is based in Santa Ana, California, and
employs approximately 4,000 worldwide. The company has operations in 24
countries and markets products in approximately 60 countries. For more
information, visit the company's Website at www.amo-inc.com.
About The Institute for Eye Research (IER)
The Institute for Eye Research Limited is dedicated to the proposition of
"Vision excellence for all people." For more than 20 years, the
Institute has collaborated with the world's leading researchers to bring
innovation in vision. An Australian not-for-profit organization, IER has
grown to be a major participant and supporter of research worldwide and
is committed to the advancement of vision science and the provision of
sustainable eye care services and education in developing communities.
For more information please go to www.ier.org.au.
Forward-Looking Statements
This press release contains forward-looking statements about AMO,
including statements by Dr. Borrmann and Professor Holden and statements
relating to development of next-generation contact lens care products.
All forward-looking statements in this press release represent AMO's
judgment only as of the date of this press release. Actual results may
differ from current expectations based on a number of factors,
including, but not limited to, unexpected delays or costs associated
with the research and development of testing standards and new formulas
for contact lens care products, continued acceptance of our current
products, and unexpected changes in competitive, regulatory and market
conditions. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation to
update these forward-looking statements. Additional information
concerning these and other risk factors may be found in previous press
releases issued by AMO and AMO's public periodic filings with the
Securities and Exchange Commission, including the discussion under the
heading "Risk Factors" in AMO's 2007 Form 10-K filed in March 2008.
Copies of press releases and additional information about AMO are
available at www.amo-inc.com.
Bookmarken
